Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

On August 15, 2022 ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, reported the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board’s ("PTAB") decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 ("the 807 patent") (Press release, ChromaDex, AUG 15, 2022, View Source [SID1234618313]). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research, Inc. from raising these arguments, or any other arguments they could have reasonably raised before the PTAB in the New York District Court lawsuit ChromaDex brought against Thorne Research, Inc. wherein ChromaDex alleges Thorne Research, Inc. is infringing the 807 patent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ChromaDex is the exclusive supplier of nicotinamide riboside chloride, Niagen, a novel form of NR backed by 20 published and peer-reviewed clinical trials. Niagen has achieved regulatory acceptance by the world’s four leading regulatory bodies including the U.S. FDA, Health Canada, the European Commission, and the Therapeutic Goods Administration (TGA) of Australia.

ChromaDex maintains a strong and growing intellectual property portfolio for its proprietary ingredient, Niagen, including for use in supplements and foods, consisting of over 40 composition, process, and method of use patents for discoveries relating to NR and other precursors to NAD+ (nicotinamide adenine dinucleotide), a molecule at the forefront of healthy aging and cellular health.